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Background: Rapid diagnostic tests (RDTs) for malaria enable proper diagnosis and have been shown to reduce
overuse of artemisinin combination therapy. Few studies have evaluated the feasibility and use of RDTs in the
private sector in Myanmar. The objectives of the study were to: 1) understand the acceptability of using RDTs in the
informal sector in Myanmar; 2) examine motivations for use among informal providers; and, 3) highlight decision-making
and knowledge of providers for diagnostic testing and treatment.
Methods: Qualitative interviews were conducted with 30 informal providers. Purposeful sampling was used to enrol
study participants in the Mon and Shan State in Myanmar. All interviews were conducted in Burmese, translated into
English, and two researchers coded all interviews using Atlas ti.
Results: Major themes identified included: 1) informal provider and outlet characteristics, including demographic and
background characteristics; 2) the benefits and challenges of using RDTs according to providers; 3) provider experiences
with using RDTs, including motivations for using the RDT; 4) adherence to test results, either positive or negative; and,
5) recommendations from informal providers to promote increased use of RDTs in their communities. This study found
that introducing RDTs to informal providers in Myanmar was feasible, resulting in improved provider empowerment
and patient-provider relationships. Specific challenges included facility infrastructure to use and dispose RDTs and
provider knowledge. This varied across the type of informal provider, with itinerant drug vendors more comfortable
and knowledgeable about RDTs compared to general retail sellers and medical drug representatives.
Conclusions: This study found informal providers in Myanmar found the introduction of RDTs to be highly acceptable.
Providers discussed improvement in service quality including provider empowerment and patient-provider relationships.
The study also highlighted a number of challenges that informal providers face which may be used for future
development of interventions.
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Anti-malarial drug resistance is a significant threat in
global efforts to control malaria. Myanmar in particular
recently reported the highest mortality due to malaria in
the Greater Mekong Sub-Region [1]. Alarming recent re-
ports indicate emergence of artemisinin resistance Plas-
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elimination programmes [2]. Presumptive treatment with
the first-line drug, artemisinin-based combination therapy
(ACT), for suspected rather than confirmed malaria cases,
may further lead to drug resistance. Rapid diagnostic tests
(RDTs) for malaria enable proper diagnosis and have
been shown to reduce overuse of ACT [3-7]. Between
2010 and 2011 the Myanmar Artemisinin Resistance
Containment (MARC) was developed, with one of the
aims to strengthen and improve access to and use of early
diagnosis and quality treatment [8]. National rapid scale-
up of RDTs is anticipated for 2014-2015, and yet inentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Sudhinaraset et al. Malaria Journal  (2015) 14:61 Page 2 of 11Myanmar there is a dearth of information on RDT use
among healthcare providers. Given that only 33% of the
Myanmar population lives in urban areas [9], understanding
RDT use in rural and remote villages is especially important.
Studies suggest that to maximize the potential of
RDTs, private informal providers play a significant role
in malaria diagnosis and treatment [10-12]. Informal pri-
vate providers are a part of the private sector, but typically
lack formal training and oversight. In Uganda, two-thirds
of medicines are delivered through the private sector,
mostly from drug shops [11]. The private sector is critical
in Myanmar, with 80% of fever patients seeking care in re-
tail private sector, typically the informal sector, compared
to only 11% going to the public sector [13]. Although pre-
vious studies demonstrate that communities perceive drug
shops as important in treating malaria, communities were
also concerned that drug shops were motivated by profits
and that they would raise the price of RDTs [12]. A num-
ber of studies in Africa and Asia suggest that community
health workers are able to prepare and interpret malaria
RDTs correctly and safely when supported by appropriate
training and clear instructions [14-16].
A few studies evaluating RDTs use and feasibility exist
in Myanmar [13,17-19]. Two studies found that intro-
duction of RDTs to relatively inexperienced providers,
including village volunteers and village health workers,
was feasible [17,19]; however, a number of challenges
arose, including insufficient instructions to discriminate
mixed P. falciparum/Plasmodium vivax from P. falcip-
arum infections [19] and findings that the number of
patients tested declined over time [17]. These studies
suggest that continued training and supervision of vol-
unteers are critical for sustaining efforts, but are also
limited by their focus only on village health workers or
volunteers. Few studies exist on acceptability, motiva-
tions and challenges of rolling out RDTs in the informal
sector in Myanmar, and importantly, whether different
types of informal providers may be most adequate in
diagnosing and treating malaria. Understanding these is-
sues will be especially important given the anticipated
national roll-out of RDTs.
This study uses qualitative data from in-depth interviews
with three types of informal providers in rural Myanmar.
The objectives of the study were to: 1) understand the
acceptability of using RDTs in the informal sector in
Myanmar; 2) examine motivations for use among informal
providers; and, 3) highlight decision-making and know-
ledge of providers for diagnostic testing and treatment.
Methods
Study context
This study was the qualitative component of a larger
community randomized, controlled trial to evaluate an
intervention to improve uptake of RDTs among informalproviders in Myanmar. A description of the pilot inter-
vention and methodology are described elsewhere [20].
Briefly, Population Services International/Myanmar
(PSI/M) rolled out the pilot intervention in rural Mon
and Shan State in Eastern Myanmar between April and
September 2013 to approximately 600 private providers.
The intervention specifically targeted the informal sector
among providers with little or no experience of diagnos-
tic testing, including grocery retail sellers, itinerant drug
vendors and medical drug representatives. General retail
sellers own small shops in the community and typically
sell a variety of goods, including non-health related
products. Itinerant drug vendors often operate from
their homes and sometimes serve as the village doctor,
with some vendors travelling to patients’ homes for care
ranging from maternal and child health services to mal-
aria diagnosis and treatment. Medical drug representa-
tives are similar to pharmacists and have knowledge
about basic drugs and treatments.
The three intervention arms included: 1) subsidies for
RDTs; 2) subsidies and one extra RDT for every five pur-
chased by providers; and, 3) subsidies and information,
education and counselling. The qualitative component of
the study was carried out in August 2013 among informal
providers who were enrolled in the pilot intervention.Description of RDT
The study used FIRST RESPONSER Malaria antigen
pLDH/HRP2 combo card test, manufactured by Premier
Medical Corp Ltd, Gujarat, India. The device reports
three potential results, indicated by three lines on the
test: one result for a control (no malaria), one for P. fal-
ciparum, and one for P. vivax.Sample and data collection
In total 30 informal providers were included in the
qualitative study. Purposeful sampling of informal pro-
viders was used for enrolment. Participants were sam-
pled by provider type (grocery retail sellers, itinerant
drug vendors and medical drug representatives), and bal-
anced low/high performing providers. The number of
providers was also similarly sampled across the interven-
tion arms of the larger study. PSI/M programme data
were used to classify low/high performing providers.
Providers who frequently restocked RDTs in their outlets
were classified as high performing, and low performers
were those who rarely restocked their supplies of RDTs.
Inclusion criteria to the study were that informal pro-
viders were enrolled in PSI/M’s intervention on RDTs,
be at least 18 years of age, and working in Mon or Shan
State of Myanmar. Researchers from PSI/M contacted a
number of informal providers before the interview to
alert them that they may be potentially interviewed.
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participated in a three-day qualitative training and con-
ducted all interviews under the supervision of a field
manager and a research coordinator. Interviews were
conducted in Burmese. Providers were asked about the
services they offered at their outlet, their knowledge on
malaria and RDTs, and their experience using the RDTs,
including challenges and perceived benefits. All inter-
views took place in a private location identified by the
providers, and most occurred at the provider outlet. In-
terviews lasted approximately 45 minutes to one hour
and were tape-recorded. A demographic form was com-
pleted after the completion of the interview.
Data analysis
All in-depth interviews were transcribed and translated
directly into English. Two researchers coded all text
using Atlas ti. Thematic analysis was used to address the
objectives of the study. First, interview transcripts were
reviewed in their entirety to identify major themes and
to check the quality of transcriptions and translations.
Next, textual information from transcriptions were ana-
lysed and codes were developed until saturation was
reached. Families of codes were developed based on larger
thematic objectives, and information was summarized
across provider types. Finally, themes across provider
types were compared and contrasted.
Ethical considerations
Ethical approval was obtained by Population Services In-
ternational’s Ethical Review Board. Research assistants
obtained informed consent from all informal providers
prior to conducting the interview.
Results
This section is organized into the major themes identified
from the study. They includes: 1) informal provider and
outlet characteristics, including demographic and back-
ground characteristics; 2) the benefits and challenges of
using RDTs according to providers; 3) provider experiences
with using RDTs, including motivations for using the RDT;
4) adherence to test results, either positive or negative;
and, 5) recommendations from informal providers to pro-
mote increased use of RDTs in their communities.
Informal provider and outlet characteristics
In total 30 informal providers were interviewed: ten gen-
eral retail sellers, ten itinerant drug vendors and ten
medical drug representatives. All completed demo-
graphic forms [see Table 1]. Nearly three-quarters of in-
formal providers had a high school education. Typically
informal providers have little to no formal medical train-
ing, although medical drug representatives and itinerant
drug vendors are more likely to have some trainingcompared to general retail sellers. In this sample, how-
ever, all informal providers had some form of medical
training, and all had been trained by PSI/M. Two had an
apprenticeship and both were medical drug representa-
tives. Seventy per cent of informal providers were female,
and the mean age was 41 years old. All but two informal
providers were owners of the outlet.
Informal providers offered a variety of services at their
outlet. All offered malaria services, and 23 offered diar-
rhoea services. About half of informal providers offered
pneumonia and family planning services, and a third
pregnancy care, post delivery care, and sexually trans-
mitted infection services; fewer general retail sellers of-
fered these services compared with itinerant drug
vendors and medical drug representatives. A small num-
ber of informal providers offered delivery (n = 6), tuber-
culosis (n = 4), and post abortion care (n = 1) services.
Three of the six outlets offering delivery were general re-
tail sellers. The mean number of patients presenting
with fever per month was 179; medical drug representa-
tives had the most fever patients, while general retail
sellers the fewest. All informal providers had RDTs in
stock at the time of interview. Supa Arte is an artemisinin-
based combination treatment package subsidized by
Population Services International. Twenty-four informal
providers said Supa Arte was the most common anti-
malarial drug they sold, and all but two said Supa Arte
was the best drug to treat malaria. All informal providers
had ACT in stock at the time of the interview.
Benefits and challenges
Acceptability and benefits of RDTs: “it’s like I have an extra
helper”
Overall acceptability of using RDTs was high among in-
formal providers. Almost all providers found that RDTs
were easy to use and that it made their work more effi-
cient. A number of informal providers discussed motiva-
tions for using RDTs, including provider empowerment
and improved provider-patient relationships. Provider
empowerment was the most commonly cited reason for
using the RDT. For instance, many providers said that it
made their jobs “easier” and that they were now capable of
diagnosing and treating patients. Informal providers often
referred to the RDT as “blood test strip”. Discerning differ-
ent types of fevers was also important for providers.
For me we used to be confused about the cause of the
disease. We thought it might be a combination of
diseases - flu, dengue fever…different fevers have similar
symptoms. Flu is associated with fevers, headaches.
Typhoid has the same symptoms. Malaria also has the
same symptoms. If I suspect that it might be two of these,
I can use the test strip to determine which illness it is. It’s
good to have the blood test strip. – General retail seller
Table 1 Demographic characteristics of providers, n (%)






Provider Type 30 10 (33.3) 10 (33.3) 10 (33.3)
Female 21 (70) 7 (70) 7 (70) 7 (70)
Age (mean) 40.5** 41.9 38.3 41.4
Education Level
Primary 1 (3.3) 0 0 1 (10)
Middle School 2 (6.7) 1 (10) 0 1 (10)
High School 19 (63.3) 5 (50) 7 (70) 7 (70)
University 8 (26.7) 4 (40) 3 (30) 1 (10)
Religion
Buddhism 26 (86.7) 9 (90) 9 (90) 8 (80)
Christianity 3 (10) 0 1 (10) 2 (20)
Hinduism 1 (3.3) 1 (10) 0 0
Ethnicity
Bamar 10 (33.3) 4 (40) 3 (30) 3 (30)
Mon 7 (23.3) 3 (30) 3 (30) 1 (10)
Kayin 5 (16.7) 0 1 (10) 4 (40)
Shan 4 (13.3) 2 (20) 1 (10) 1 (10)
Kayar 1 (3.3) 0 1 (10) 0
Indian 1 (3.3) 1 (10) 0 0
Paou 1 (3.3) 0 1 (10) 0
Palaung 1 (3.3) 0 0 1 (10)
Number of fever client/month (mean) 178.6 231 192.8 112
Buying cost of RDT (mean) 107 kyats 105 kyats 120 kyats 95 kyats
Selling cost of RDT (mean)*** 278 kyats 295 kyats 390 kyats 150 kyats
**Statistical difference for sex, chi2 p = 0.000.
***Statistical difference for selling cost of RDT, anova p = 0.0340.
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malaria or not. If I didn’t have it, I wouldn’t know
how to treat someone. Using the test strips, I will be
able to give better treatment. – Itinerant drug vendor
Other providers discussed how the RDT greatly im-
proved treatment practices. For example, one provider
discussed how s/he no longer needs to guess which
medicine to give because of the RDT.
It’s good if I have the blood test strip because previously I
just gave out medicine based on guessing. Now, because
I have the test strip, it’s more accurate. I can know the
result and if the patient has malaria I can give Supa
Arte. If there’s no malaria, I won’t give it to them. –
Medical drug representative
Almost all providers who used RDTs discussed how
this increased their confidence in their medical practices.It’s like I have an extra helper [having the RDT], who
helps me figure out the causes of patient illnesses. It’s
not just me trying to figure it out. I’m happy to have
the blood test strip. – Itinerant drug vendor
Improvements in practices also led to increased per-
ceived patient volume and improved patient-provider re-
lationships. A majority of providers said that their
patient flow increased after being trained in RDT use
and stocking RDTs. A number of informal providers dis-
cussed how because they were part of the community,
patients preferred to go to their outlets rather than larger
hospitals, in part because of cost and transportation issues.
A number of providers also discussed that patients had
more trust in the providers as a result of the RDT.
Their [patients] perceptions are positive because in the
past they have to take the tests on the slides, but now
they know the results immediately so they are happy.
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disappointed. Now they can take the test easily. They
trust me even more. – Itinerant drug vendor
Increased trust and stature in the community also led
to increases in patient flow.
After using the RDTs, patients are more confident in my
experience and also my wife’s experience. In addition, my
wife and I give the RDTand drugs cheaper compared to
other shops. Clients are more likely to recommend others
to our shop. – Medical drug representative
Finally, some informal providers were also motivated
by altruistic reasons. Many informal providers had a
good understanding of their communities and wanted to
improve the health of their communities, not for monet-
ary or personal gains, but because they cared for the
people they served.
For me, profit isn’t my first priority. It [RDT] helps me
confirm quickly whether people have malaria or not. I
wouldn’t say it’s profitable, but it does help me…It
helps them [patients] a lot. – Itinerant drug vendor
[When asked why s/he used RDTs]: I want my village,
my community to develop. – Itinerant drug vendor
A few providers discussed giving the RDT and medica-
tions for free, especially for low-income or rural patients.
I give it free to some patients. For patients who live up on
the hill because they are so poor. They are malnourished.
I feel sorry for them so I give them free treatment. Free
testing. I give drugs for free. It’s people from Lahu village.
It’s very far from here. It’s East of here. If they come to
me, I don’t charge any money. – Itinerant drug vendor
Provider challenges with RDT use
Informal providers reported few challenges in using
RDTs. One challenge reported was having appropriate
infrastructure to draw blood. For example, a small num-
ber of providers discussed the type of infrastructure
needed to dispose of needles adequately, mostly due to
fears concerning HIV. Despite using a new needle for
every RDT exchange, one provider discussed perceived
risks with using needles based on past experiences.
I have two colleagues that got HIV from used needles…
Therefore, I take a lot of care in disposing needles. –
Itinerant drug vendor
It’s because of the ‘four alphabet disease’ [referring to
AIDS]. They [patients] are afraid of taking the testbecause they are worried that they might get the
disease and then won’t know what to do. That’s their
thinking and why they are worried to take the test.
Only after starting this shop did I start doing the
blood test. In my previous shop, I couldn’t do much. I
only gave the blood test when their symptoms were
really serious. – Medical drug representative
Other less common challenges a few providers men-
tioned included quality of the RDTs themselves, includ-
ing uncertainty with test results when lines either do not
appear or appears between two results, not having
enough demand from patients (discussed further below),
and patients afraid of taking the RDT because of blood
pricks. There were some differences in challenges re-
ported by provider type. All itinerant drug vendors were
comfortable using RDTs while a few general retail sellers
discussed not being qualified to give the RDT because of
lack of medical experience.
The main problem is that I am scared. I’m afraid to
use it. I’m not confident in myself. It’s not from the
customer side. – General retail store
Experiences with use
Understanding of the purpose of RDTs
The majority of all three types of informal providers
knew that the purpose of the RDT was to detect malaria
and that a RDT is needed to confirm malaria.
The most certain method [for detecting malaria] is
using blood tests, and it’s [RDT] quicker and easier.
Otherwise you have to guess based on symptoms. –
Itinerant drug vendor
It [RDT] is useful for malaria. I can know if the
patient has which type of malaria. – Medical drug
representative
In addition, nearly all informal providers were also
aware that the RDT could distinguish between P. falcip-
arum vs P. vivax.
Selective use of RDTs for suspected malaria
While informal providers knew the purpose of RDTs,
and reported several benefits for using RDTs, this know-
ledge and perceived benefits did not necessarily translate
into universal and consistent use for each patient who
presented with fever. Informal providers reported using
RDTs only for patients they suspected had malaria, ra-
ther than any patient who presented with a fever. The
reasons for suspected malaria varied considerably among
providers, including suspected symptoms, specific vul-
nerable populations and seasonality. A large number of
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sented with specific symptoms: fever with chills or
sweating or “rigour”, high fever that comes and goes, or
prolonged or “regular” fever.
Some patients have fever with chills and rigor. Some
patients have low-grade fever with chills. If the fever is
high, the test will show that it’s positive. – General
retail seller
The fever is regular [if it is malaria]. For example if a
patient gets a fever during the night time, the next day
they’ll get the fever at the same time the next night.
Normally you get a fever, sweat, and then the fever
goes down. Then the fever comes up again around two
or three times a day. – Itinerant drug vendor
A few informal providers, especially itinerant drug ven-
dors, described treating a fever first with common medi-
cine and using a RDT only if the fever persisted.
I will give drugs for fever…Then I say if there are
symptoms still left on the next day, I will conduct the
RDT test. – Itinerant drug vendor
If a patient has a high temperature the first day, I
give drugs. I give antibiotics and paracetamol. The
next day he comes back but still has fever with high
temperature and certain kind of vomiting and
headache, then I will suspect that he has malaria.
Then I will give him the test. – Itinerant drug
vendor
A smaller number of informal providers suspected mal-
aria if the patient had muscle aches, headaches, vomiting,
loss of appetite, diarrhoea, or jaundice.
Apart from specific symptoms, other reasons why infor-
mal providers suspected malaria were geographic location,
profile of the patient, and/or season. Several informal pro-
viders discussed that malaria was only common in certain
types of patients: migrant or field workers, those who
worked on rubber plantations or mines, or those who had
travelled north.
[Describing last time used RDT]: That patient came
back from Myawaddy [border between Myanmar/
Thailand]. They have malaria there. People returning
from there typically have malaria. – Itinerant drug
vendor
Yes people who live here don’t have malaria. I don’t
find any malaria from them. I found only one patient
who returned from the North region. – General retail
sellerInformal providers also suspected malaria for patients
who worked in the field or mines, of which one informal
provider also associated with being poor.
Malaria is common in field workers…most of whom
can’t afford [RDT], are poor. – Medical drug
representative
[Describing last time used RDT]: He’s from a gold mine
village. Malaria is common in those mining sites. –
General retail seller
I think it [malaria] may be [present], especially for
people living on the hilly region and also in migrant
workers. People on the hills are working in the rubber
fields. – Itinerant drug vendor
Lastly, informal providers also suspected malaria dur-
ing the rainy season, or for a patient who had malaria
previously.
During the rainy season, malaria is caused by
mosquito bites. They have dry skin. Their lips become
white, and they have fever. Then we guess that they
have malaria. – Itinerant drug vendors
In this area, there’s a specific season for malaria
patients. During the summer season, there are few
patients the entire day. During the winter and rainy
season there are many patients that come to the shop. –
Medical drug representative
The one that I should give the test to is someone who
has had malaria before. If he or she has had malaria
before and now they have fever, I must give the test. –
Medical drug representative
Relationship of RDT use to perceived context of malaria:
“there’s no more malaria”
This selective use of RDTs for only suspected malaria
may in part be due to the prevailing belief among many
informal providers that malaria incidence and prevalence
is very low. Many informal providers believed that there
was little or no malaria in the area.
We used to have many malaria fever cases in the
region, but no longer. We used to have a lot of malaria
before. – General retail seller
When I came here there was a lot of malaria cases –
not many – but at least three cases a month. Now
there’s no more malaria. I hear about one or two
people a year…It’s not that malaria is eradicated, but
it’s rare. – Itinerant drug vendor
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decreasing malaria to the numerous efforts made by
non-profit organizations in recent years.
Here, people have experienced malaria before. Later,
after [international non-governmental organization]
came in, it disappeared because [international
non-governmental organization] fights for malaria. –
Itinerant drug vendor seller
Two to three years ago this village was famous for
malaria, and the groups [health] gave mosquito nets
and talked, so malaria is very low. – General retail
seller
Use of RDTs for all fever cases: differences of motivations
by provider type
While the majority of informal providers only used
RDTs if they suspected malaria, a small number of infor-
mal providers reported they would use it for all fever
cases, as seen with this itinerant drug vendor who em-
phasized the benefit to the patient
I didn’t find anyone that I suspected had malaria
[previously], but now that I have the RDT, I give the
test whether it’s necessary or not if I find a fever case.
If I do that, it’s beneficial for the patients. If it’s not, it’s
useless. So, if I see a fever case, I always give a blood
test. – Itinerant drug vendor
One medical drug representative knew that s/he ad-
ministered RDTs more frequently than needed in order
to alleviate the patient’s doubts.
If they are willing to take the test, I will give the test. If
you think that I should give all those patients blood
tests, I don’t think so because [it’s] based on my
diagnosis of their symptoms. I end up giving it to them
because they are willing to help them alleviate their
doubts. Actually, not all of them need testing. I give
more tests than I should because the patients want to
alleviate their doubts. – Medical drug representative
For this general retail seller, s/he administered RDTs
because s/he knew that was the only way to confirm
malaria.
You can’t be sure if you don’t take the test. It’s better if
you take the test”. – General retail seller
Of the small number of informal providers who re-
ported using RDTs for all fever cases, the motivations
for use appear to vary by provider type. General retail
sellers appear to be less comfortable relying on clinicaljudgment to assess suspected malaria and administer
RDTs for all fever cases in order to help their clinical
decision-making.
Adherence to RDT result
Positive RDT result
The majority of results from RDTs administered were
negative, although of those that were positive, providers
recall a P. falciparum diagnosis more frequently than P.
vivax. There was variability in how informal providers
interpreted results, and many providers did not know
how to distinguish between P. falciparum and P. vivax
based on the results. Some providers said one line means
no malaria but two lines means malaria, while others
said the middle line means malaria and the third line is
severe malaria.
Informal provider treatment knowledge was greater
for P. falciparum compared to P. vivax. Supa Arte was
the most common drug prescribed for P. falciparum;
however for serious cases, a few informal providers were
scared to treat and would refer patients to the hospital.
A few informal providers also did not know what drug
to prescribe. If the test result was positive for P. vivax,
informal providers were unclear which drug was best to
prescribe. The drugs mentioned by informal providers
for treating P. vivax included a number of drugs, includ-
ing ACT, artemisinin monotherapy and antibiotics. As
one general retail seller said, “There is no clear drug for
P. vivax”.
Typically if the test result showed P. falciparum, infor-
mal providers prescribed Supa Arte and for P. vivax, in-
formal providers referred patients to the hospital.
“If the [RDT] show in P. vivax, there is malaria and
these drugs [Supa Arte] cannot be given for this type
and the person needs to be referred to the clinic or
hospital. If it is in P. falciparum, there is also malaria
and these drugs [Supa Arte] can be given. If I find
both types, I do not know what it is so I must refer this
patient to the hospital.” – Medical drug representative
Negative RDT result
Many informal providers said that after a negative RDT
result they would treat the patient for common cold or
flu. Informal providers mentioned an array of medicines
they would prescribe, most commonly giving antibiotics.
Other drugs they would give include ACT, artemisinin
monotherapy and vitamins. A few informal providers
said they would conduct other tests (blood pressure),
refer patients to a hospital for further testing, or pre-
scribe nothing since they did not have the right treat-
ment. Several informal providers understood not to
prescribe anti-malarials if the RDT result showed no
malaria.
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These drugs [Supa Arte] are only for people who have
the disease. – General retail seller
I wouldn’t give anti-malarials to him. It’s not suitable
for the patient if they don’t have malaria. So, if it’s just
a fever, I will just give common drugs. – Itinerant drug
vendor
Several providers also gave examples of not prescribing
anti-malarials for the last time a patient tested negative.
I tested the child, but no malaria was found and I
gave no anti-malarial drugs. – General retail seller
“I did the test. Even she said she has had history but
the blood test showed the red line in the ‘C’ control,
not in ‘P. falciparum’ and ‘P. vivax’. So I dared not give
the drugs. I did not give any drugs to her. The fever is
high but the result did not show positive” – Medical
drug representative
However, quite a few informal providers also gave ex-
amples of when the RDT was negative but they still gave
anti-malarials, either because the patient did not get bet-
ter, patient demand, or the informal provider believed
the patient had malaria despite the negative RDT result.
Another patient was also like this. He said he had
fever for one week, high and intermittent for regular
time. So I did the test but it showed in the ‘C’ control,
not in ‘P. falciparum’ and ‘P. vivax’. He said she had
malaria really and please give him anti-malarial
drug. So I gave the green card [Supa Arte] for adult
drugs…One week later, he came back to me and I
asked how was your fever so he said it was relieved. –
Medical drug representative
All were negative, just one line. I didn’t give malaria drugs
at the time, only normal drugs. The patient didn’t get
better. The next day, I gave quinine and artesunate. Only
then did he get better. – Medical drug representative
Sometimes patients take the drugs – Supa Arte –
based on their own decision. Because this is the shop, I
have to sell it to them. – General retail seller
Prescribing anti-malarials even after a negative RDT
was more common with general retail sellers and med-
ical drug representative.
Informal provider recommendation
Informal providers gave a number of recommendations
for improving their experiences with RDTs and tosupport uptake among patients. In particular, they sug-
gested improved training on specific areas, undertaking
demand creation activities, and ensuring quality RDTs
and consistent supply. This study also identified a num-
ber of knowledge gaps in provider training including
treatment options for P. falciparum vs P. vivax. Add-
itionally, many providers were unsure of what to pre-
scribe for negative RDT results.
The most common recommendation by informal pro-
viders was to undertake demand creation activities. One
general retail seller said, “If the patients doesn’t accept
this [RDT], we can’t do anything”. This theme was
echoed by many informal providers who discussed the
importance of patient acceptability for use of the RDT.
Many informal providers discussed increasing patient
knowledge regarding malaria, including general malaria
knowledge, when to get tested with a RDT, and where
patients can get the test. Informal providers recom-
mended a number of community health and marketing
strategies, including using posters, TV, billboards, and
information leaflets to help increase knowledge.
Advertise it. To get awareness from most people, you
must put some posters and billboards in the crowded
places like the markets. Some watch the TV but others
don’t. I also stick the posters in the shop, but I think this
poster is a little small. – Medical drug representative
One informal provider gave a specific recommenda-
tion to work closely with communities and leaders in
the villages.
Like I said before, discussing with village heads maybe
in the schools or village meetings. When there are
many villages together, you don’t need to recruit by
yourself. On those occasions, you can educate them all
on malaria prevention, treatment, availability of
malaria treatment, places where it’s available, don’t
be afraid of malaria. Other promotional items to help
remind people about malaria and items that can be
given to people to help remind people. – Itinerant drug
vendor
Finally, informal providers also stressed the importance
of ensuring a consistent and reliable supply of RDTs.
I think it’s best if the RDTs are available all the time.
Although we use it infrequently, we should have it
when we need it. Availability is important. – General
retail store
Discussion
The informal private sector makes up a significant por-
tion of malaria care in Myanmar, yet little is known
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and malaria treatment. This study demonstrated high ac-
ceptability of using RDTs. Informal providers felt the
RDT was easy to use and they experienced minimal
challenges. This finding reflects results from past studies
in other contexts [10,11,21-25]. This study also identified
several motivations for use, including increased provider
empowerment to diagnose malaria and improved provider-
patient relationships. Provider empowerment, in particu-
lar, was cited as a common reason for wanting to use
RDTs as it improved their ability to make more informed
diagnostic decisions.
This study found that the majority of informal pro-
viders used RDTs only for patients they suspected had
malaria. Informal providers suspected malaria for pa-
tients who presented with a specific type of fever: fever
with chills, fever that returns, or fever that is regular. In-
formal providers also suspected malaria for particular
types of patients: those who had returned from Thailand
or north, those who had worked in the field (rubber,
gold, mines, migrant workers), or those who had malaria
previously. Informal providers’ perception of suspected
malaria for particular types of patients may be accurate
given that artemisinin resistance has emerged along the
Thailand and Myanmar border in the past decade [26]
and that malaria prevalence is more common in certain
populations, such as migrant or field workers [27].
Most informal providers believed malaria incidence
and prevalence were very low in their communities, and
that malaria was decreasing significantly due to recent
prevention efforts by various organizations. This is in
stark contrast to existing reports of high transmission
and endemicity, particularly in the Mon and Shan State
[2]. However, more recent monitoring and evaluation
data suggests that only 8% of febrile cases tested for mal-
aria actually had malaria [28]. Despite recent declines in
transmission, Myanmar continues to account for the
majority of malaria-related morbidity and mortality in
the region, and feasibility challenges will further detract
from a goal of elimination [29]. Providers’ perceptions
that malaria has been eliminated in their communities
combined with targeted RDT use may further exacerbate
these challenges.
Although most informal providers did not prescribe
anti-malarials for a negative RDT result, a few did, in
particular general retail sellers and medical drug repre-
sentatives, which raises a number of clinical concerns.
Some informal providers also struggled with interpreting
the RDT correctly, as well as knowing what to prescribe
for positive results, especially for P. vivax. While the use
of RDTs is feasible and acceptable by informal providers
in Myanmar, there is a need to continue support and
training for informal providers on treatment knowledge
and adherence to RDT results. In particular, a focus onwhat to do for a negative RDT result is needed in future
studies. This study found that many informal providers
treated for the common cold or flu and prescribed an
array of medicines for negative RDT results. This is cor-
roborated by other studies that also found high preva-
lence of ineffective drug use, particularly antibiotics,
after the introduction of RDTs [3,30]. This study demon-
strated a higher capacity among itinerant drug vendors
for RDT result adherence compared to other types of in-
formal providers. Interventions focused on improving
diagnosis and treatment of patients should consider the
type of informal provider involved, and particularly
training on when to use antibiotics.
As in any study, there are limitations to these results.
First, the study is a small, qualitative study and therefore
may not be generalizable to other areas of Myanmar or
contexts. Future studies should validate these findings in
other settings in Myanmar. Second, this study was con-
ducted in the context of a larger community, randomized
intervention of provider incentives to increase RDTs. The
intervention included providing informal providers with
subsidized RDTs and either information, education and
counselling or a financial incentive in the form of one free
RDT for every four RDTs purchased. This might specific-
ally impact findings that provider motivations were less fi-
nancially driven, and more altruistic-driven. However,
other findings in Myanmar have also found altruistic moti-
vations among private providers [31]. Providers were also
purposefully sampled to include a balance of each inter-
vention arm. More detailed information about the larger
study is described elsewhere [20].
Despite these limitations, this study highlights a number
of recommendations and future research priorities. First,
informal providers need further specific training on proce-
dures for a negative RDT and cases of P. vivax. Second,
raising community level awareness of malaria symptoms
and specifically about RDTs is crucial, given that these
providers respond to the needs of people within their
communities. Engaging with community leadership is an
important strategy to building trust and improving rela-
tionships between public health programmes and com-
munities. Moreover, due to perceptions that malaria is
eliminated in their communities, providers should also be
trained on when to use RDTs and on the general under-
standing of malaria transmission and prevalence. Finally,
ensuring adequate RDT and drug supplies will be import-
ant for containment and treatment of malaria in Myanmar.
Both public and private sector should engage with one an-
other to ensure adequate supplies of commodities and that
supplies are consistently available to providers.
Conclusion
This study found that introducing RDTs to informal pro-
viders in Myanmar was highly acceptable, resulting in
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relationships. Informal providers faced challenges with
adequate facility infrastructure to use and dispose RDTs
and lack of provider knowledge around malaria testing
and treatment. Providers also had challenges with inter-
preting RDT results. This suggests that refresher train-
ings would be helpful for future interventions with these
types of providers. Perceived low prevalence of malaria
also influenced use of RDTs. This study informs future
interventions on RDT use in Myanmar, including spe-
cific topics to cover in trainings and considerations for
working with certain types of providers.
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